Karen Eugeni
Investor Relations Kontakt bei Bellus Health (Innodia), Inc.
Profil
Karen Eugeni is Vice President of Business Development and Communications for Innodia, Inc. Prior to that, she held various positions at Ecopia BioSciences, Inc. and BioChem Pharma, Inc. (now part of Shire Pharmaceuticals).
She has 20 years of business experience, including running her own business and ten years in the biotechnology industry.
Ms. Eugeni received a Bachelor's degree in Microbiology, Immunology and Chemical Engineering and an MBA from McGill University.
Aktive Positionen von Karen Eugeni
| Unternehmen | Position | Beginn |
|---|---|---|
Bellus Health (Innodia), Inc.
 Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | Investor Relations Kontakt | - |
Ehemalige bekannte Positionen von Karen Eugeni
| Unternehmen | Position | Ende |
|---|---|---|
Biochem Pharma, Inc.
 Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | Corporate Officer/Principal | - |
Ecopia BioSciences, Inc.
 Ecopia BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Ecopia is finding novel anticancer therapies from soil-dwelling micro organisms that are as of this day one of the most prolific sources of these drugs. Their current focus is ECO-4601, a new small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary tumor growth in the brain. Just like well-known chemotherapies such as doxorubicin and daunorubicin, ECO-4601 comes from microorganisms that live in common soil. ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the Decipher® technology | Corporate Officer/Principal | - |
Ausbildung von Karen Eugeni
| McGill University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Ecopia BioSciences, Inc.
Ecopia BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Ecopia is finding novel anticancer therapies from soil-dwelling micro organisms that are as of this day one of the most prolific sources of these drugs. Their current focus is ECO-4601, a new small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary tumor growth in the brain. Just like well-known chemotherapies such as doxorubicin and daunorubicin, ECO-4601 comes from microorganisms that live in common soil. ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the Decipher® technology | Health Technology |
Biochem Pharma, Inc.
Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | Health Technology |
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | Health Technology |
